GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to recent hires on Dec. 1, 2025. The company issued restricted stock units totaling 21,570 shares to 21 non-executive employees under its Inducement Equity Incentive Plan as an employment inducement.

The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and the remainder vesting on each one-year anniversary thereafter, subject to continued employment with GRAIL or its successor/subsidiary.

MENLO PARK, Calif., Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Nov. 30, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302629435.html

SOURCE GRAIL, Inc.

FAQ

What did GRAIL (GRAL) announce on December 1, 2025 about equity awards?

GRAIL announced inducement restricted stock unit grants totaling 21,570 shares to 21 recently hired non-executive employees under Nasdaq Rule 5635(c)(4).

How do the GRAIL (GRAL) RSUs vest and when is the first vesting date?

The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and annual vesting on each one-year anniversary thereafter.

Under which plan were GRAIL (GRAL) inducement awards granted?

The awards were granted under GRAIL's Inducement Equity Incentive Plan and the company's restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

Who were the recipients of the GRAIL (GRAL) inducement RSUs?

The RSUs were granted to 21 recently hired non-executive employees as an inducement material to their acceptance of employment.

Do GRAIL (GRAL) inducement RSUs require continued employment to vest?

Yes. Vesting is subject to continued employment with GRAIL (or any successor or subsidiary) through each vesting date.

Was the GRAIL (GRAL) grant made in compliance with Nasdaq rules?

Yes. The company stated the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) for inducement awards.